Open AccessDo propranolol and amisulpride modulate confidence in risk-taking?
Author(s) -
Johanna Habicht,
Magda Dubois,
Jochen Michely,
Tobias Hauser
Publication year - 2022
Publication title -
wellcome open research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.298
H-Index - 21
ISSN - 2398-502X
DOI - 10.12688/wellcomeopenres.17423.1
Subject(s) - amisulpride , ns3 , psychology , confidence interval , medicine , psychiatry , schizophrenia (object oriented programming) , immunology , hepatitis c virus , virus , antipsychotic
Background: Making rational choices and being able to consciously reflect on the goodness of these choices is important for successfully navigating the world. Value-based decisions have been extensively studied, but we know little about the factors that influence our confidence in value-based choice. Particularly, we know very little about the neurotransmitters that may mediate these processes. Methods: In this double-blind, placebo-controlled study design involving 61 healthy human subjects (30 female), we assessed the contributions of dopamine (400 mg amisulpride) and noradrenaline (40 mg propranolol) to value-based decision making and the subjective confidence therein in a monetary risky gambling task. Results: We did not find any significant effect of either of the two pharmacological manipulations, neither on value-based decision making, nor on subjective confidence. Conclusion: We discuss these (null) findings, and release all relevant data and code. This will allow researchers to further interrogate the data, to counteract publication biases in favour of significant findings, and to use our study as a source for balanced meta-analyses.